News & Events
February 7, 2024
Dr. Janet Woodcock: A Visionary Leader in Regulatory Science and the Inspirational Force behind the Creation of Critical Path InstituteIn her nearly four decades with the U.S. Food and Drug Administration, Dr. Janet Woodcock personally transformed the culture of the agency in ways that will be sustained and have an everlasting impact. She understood that for the next stage of FDA’s regulatory mission to be effectively achieved, it would need to be grounded on......
January 26, 2024
Critical Path’s Clinical Outcome Assessment (COA) Program Announces Industry Co-Directors for 2024: Carson, Mowlem and PhillipsThe Patient-Reported Outcome (PRO) Consortium welcomes Robyn Carson, MPH, Vice President and Head of Patient-Centered Outcomes Research at AbbVie, as the 2024 PRO Consortium Industry Co-Director. Ms. Carson brings 17+ years of patient-centered research and expertise to this role and has been a leader within the PRO Consortium since its inception in 2008, co-chairing the Irritable......
January 23, 2024
C-Path, CPP Share Manuscript That Redefines Parkinson’s DiseaseC-Path and its Critical Path for Parkinson’s Consortium are pleased to share a new manuscript that redefines Parkinson’s disease based on advances in the understanding of the underlying biology of disease. C-Path is honored to serve as a catalyst for bringing together diverse stakeholders from around the world to share promising results in new ways. It’s clear. The best......
December 21, 2023
Flexible approaches to eCOA administration in clinical trials: The site perspectiveThe Critical Path Institute convened the Support Flexible Approaches to PRO Data Collection project as part of the eCOA: Getting Better Together Initiative which was instigated to identify and address common challenges and drive positive change with eCOA implementation in clinical trials. Click here to read the publication in its entirety on ScienceDirect....
November 8, 2023
C-Path Partners with Unite4TB to Create a New Dawn in the Fight Against TuberculosisC-Path is proud to be part of UNITE4TB, a public-private partnership funded by the Innovative Medicines Initiative and part of the AMR Accelerator. A new dawn in the fight against Tuberculosis UNITE4TB, the largest public-private collaboration in tuberculosis drug development, announces start of clinical trials 8 November 2023. Today, UNITE4TB, an international public-private partnership......